Clearmind Medicine Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| FY2026 Annual Report on Form 20-F (Fiscal Year Ended October 31, 2026) | 20 Jan 2027 |
Monitoring Framework
Key Performance Indicators
Phase I/II Clinical Trial Dosing Completion (CMND-100) Quarterly24.0Target: Complete Part A (24 participants across Cohorts 1-4 successfully dosed)
Cash and Cash Equivalents Quarterly11.4MTarget: Maintain sufficient runway for clinical trials
Patent Portfolio Size (Granted Patents) Annually31.0Target: Expand global IP protection across key jurisdictions
Watch Items
- Going Concern Status and Cash RunwayTrigger: Cash reserves falling below $3.0M without additional non-dilutive or equity financingAction: Evaluate alternative financing options, strategic partnerships, or cost-reduction measures to preserve capital.
- Phase I/II Clinical Trial Progress for CMND-100Trigger: Initiation of Part B / Phase II efficacy cohorts in Alcohol Use Disorder (AUD)Action: Monitor patient recruitment rates, safety data readouts, and regulatory feedback from the FDA and institutional review boards.
- Nasdaq Minimum Bid Price ComplianceTrigger: Share price falling below $1.00 for 30 consecutive business daysAction: Assess the necessity of further share consolidations (reverse splits) or corporate actions to maintain listing requirements.
Research as of 20 Jun 2026